To ask Her Majesty’s Government whether appropriate treatment for patients with plasma disorders such as haemophilia and primary immunodeficiency, as provided for under the statutory scheme for branded medicines, will continue to be provided following the review of that scheme by the Department of Health.

We are continuing to consider carefully all the consultation responses. It is important we get these changes right for patients, the National Health Service and industry. We want to look in particular at the impact on small and medium sized businesses, while securing the medicines patients need at a cost which the NHS can afford.